{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-26-000071","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2026-08-24T11:01:19+00:00","discovered_at":"2026-08-24T11:05:03.851800+00:00","generated_at":"2026-08-24T11:05:39.270670+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ANI Pharmaceuticals appoints Henry Gosebruch to board; director Shanmugam resigns","bullets":["Henry Gosebruch appointed to ANI board effective Aug 19, 2026; term expires at 2027 annual meeting.","Gosebruch is CEO of Lakefront Biotherapeutics (formerly Galapagos) since May 2025; ex-CEO of Neumora, ex-EVP Chief Strategy Officer at AbbVie.","Gosebruch receives initial restricted stock award with grant date fair value $525,000, vesting in 3 equal annual installments.","Samy Shanmugam resigned as director effective Aug 23, 2026; remains Head of R&D and COO of New Jersey Operations.","Gosebruch brings 30+ years experience; expected to strengthen business development and capital allocation as ANI accelerates Rare Disease transformation."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-26-000071","json":"https://secwatch.observer/filing/0001023024-26-000071.json","markdown":"https://secwatch.observer/filing/0001023024-26-000071.md","text":"https://secwatch.observer/filing/0001023024-26-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/0001023024-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302426000071/ani-20260819.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-24T11:05:39.270670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}